China Biotech Services Holdings
China Biotech Services Holdings Limited, commonly referred to as CBSH, is a prominent player in the biotechnology sector, headquartered in China (CN). Established in 2001, the company has made significant strides in providing comprehensive services across the biopharmaceutical and healthcare industries, focusing on drug development, clinical trials, and regulatory compliance. With a strong operational presence in major regions of China, CBSH offers a unique suite of services that includes laboratory testing, data management, and consulting. Their commitment to innovation and quality has positioned them as a trusted partner for pharmaceutical companies seeking to navigate the complexities of the biotech landscape. Notable achievements include successful collaborations with leading global firms, underscoring their market position as a key service provider in the rapidly evolving biotech industry.
DitchCarbon Score
How does China Biotech Services Holdings's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
China Biotech Services Holdings's score of 34 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
China Biotech Services Holdings's reported carbon emissions
In 2023, China Biotech Services Holdings, headquartered in CN, reported total carbon emissions of approximately 21,973,000 kg CO2e. This figure includes about 6,908,630 kg CO2e from Scope 1 emissions and approximately 15,064,370 kg CO2e from Scope 2 emissions. The company has not disclosed any Scope 3 emissions data for this year. Comparatively, in 2022, the total emissions were about 21,163,930 kg CO2e, with Scope 1 emissions at approximately 6,480,150 kg CO2e and Scope 2 emissions at around 14,683,780 kg CO2e. This indicates a slight increase in total emissions year-on-year. China Biotech Services Holdings has set ambitious climate commitments, aiming for a 90% reduction in absolute carbon emissions for Scopes 1 and 2 by 2050, using 2023 as the base year. Additionally, the company has submitted a letter of commitment to reduce its Scope 1, 2, and 3 greenhouse gas emissions, with validation from the Science Based Targets Initiative (SBTi) expected in 2026. The company's emissions data is not cascaded from any parent organization, and all reported figures are derived directly from China Biotech Services Holdings Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 30,000 | 00,000 | 00,000 | 0,000 |
| Scope 2 | 467,000 | 000,000 | 000,000 | 00,000,000 |
| Scope 3 | 43,700 | 00,000 | 00,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
China Biotech Services Holdings is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
